Our innovation SYS-0108
An innovative approach against Alzheimer’s disease
Alzheimer’s disease is one of the greatest medical and scientific challenges of our time. Currently, no treatment has demonstrated the ability to stop or sustainably slow the progression of this devastating disease. At SYNAPTYS neuroscience, we have taken on this challenge by developing a completely new therapeutic approach: SYS-0108.
SYS-0108:
A new vision for a multifactorial disease
Unlike current treatments that focus on a single mechanism, SYS-0108 takes a multimodal approach, combining several mechanisms of action to attack Alzheimers’s disease from different angles, thereby increasing effectiveness. This approach is particulary relevant for such a complex disease, which simultaneously affects multiple biological processes in the brain.
Our solution stands out in two major aspects:
1. Targeting the glutamatergic pathway: The central role of glutamate
- Glutamate is a key neurotransmitter involved in the transmission of neural signals, particulary in critical areas like the cortex and hippocampus, which are linked to higher cognitive functions. In Alzheimer’s disease, the regulation of the glutamatergic pathway is severely disruped, leading to an excessive accumulation of calcium in neurons through NMDA receptors, causing cell death.
- SYS-0108 includes memantine, an NMDA receptor antagonist, which helps restore neuronal transmission by blocking the excess glutamate while preserving normal functions. This treatment has already proven its short-term efficacy in clinical studies, but our innovation goes further by enhancing its action through synergy with vitamin D.
2. Calcium modulation and the synergistic impact of vitamine D
- Recent studies have highlighted the importance of vitamine D in regulating neuronal calcium signaling, a crucial aspect for memory and learning. Vitamin D receptors (VDRs), abundantly present in the hippocampus, protect neurons by regulating intracellular calcium and reducing oxidative stress.
- SYS-0108 combines memantine with vitamine D, not only to stabilize calcium flow in nerve cells but also to potentially inhibit neurodegenerative mechanisms. This unique combination works in synergy to enhance the efficacy of memantine while leveraging the neuroprotective properties of vitamin D.
Promising results:
More than13 years of research
The development of SYS-0108 is based on more than 13 years of intensive research carried out by an international team of 18 researchers across France, the United States, Canada, and Spain. Our bibliographic research shows over twenty studies confirming our hypotheses. Our initial preclinical proof-of-concept not only establishes the synergistic power of the molecules but also demonstrates the neuroprotective effects of our solution on neuronal death and neuritic networks. Additional early evidence also indicates positive trends with significant improvements in cognitive functions and a reduction in disease markers in animal models.
Key figures:
Years
of scientific research
Committed researchers
(US, Canada, France, and Spain)
More than 20 publications validating our approach
A global impact:
Changing the corse of the disease
Our ultimate goal with SYS-0108 is to slow down, or even stop, the progression of Alzheimer’s disease by targeting multiple biological mechanisms simultaneously. By acting even before the onset of the most severe symptoms, this treatment could not only improve the quality of life for patients and families, but also reduce the costs associated with long-term care and ease the burden on public and private healthcare systems worldwide.
Our Research & Development Process
Our research is conducted in collaboration with renowned public service laboratories, such as INSERM, as well as leading private institutions like NeroSys, recognized among the best in the field. These collaborations give us access to cutting-edge resources and technologies, while benefiting from the expertise of top-level researchers.
Additionally, we are supported by expert committees and a pharmaceutical laboratory on specific aspects of our development. Their support and strategic guidance are crucial to optimizing our approach and ensuring that we remain at the forefront of innovation in Alzheimer’s treatment.
Together, these elements form the solid foundation of our research and development process, enabling us to move forward with confidence toward our goal: to offer an effective and sale solution for patients with Alzheimer’s disease.
Next steps in development:
From the lab to clinical trials
We have reached key milestones in our research, but several phases lie ahead before we can offer a therapeutic solution to patients.
We are committed to continuiing our collaboration with industry experts to successfully complete these critical phases and provide an innovative and effective solution against Alzheimer’s disease.